alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–147 of 147 studies with an author at Duke Medical Center (US) (page 6 of 6) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 147 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neuropsychological performance in advanced age: influences of demographic factors and Apolipoprotein E: findings from the Cache County Memory Study

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Clinical neuropsychologist 2008-06-10

The Cache County Study of Memory in Aging (CCMS) is an epidemiological study of Alzheimer's disease (AD), mild cognitive disorders, and aging in a population of exceptionally long-lived individuals (7th to 11th decade). 1 key finding →

Participants: 507 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Molecular genetics and metabolism reports 2023-08-21

Creatine transporter deficiency (CTD) is a rare X-linked disorder of creatine transport caused by pathogenic variants in SLC6A8 (Xq28). 4 key findings →

Participants: 12 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies

✓ Peer-reviewed alzhub usefulness score 42 out of 100. American Journal of Neuroradiology 2025-07-10

Alzheimer disease (AD) is the leading cause of dementia, with an estimated 6.9 million Americans aged 65 and older living with Alzheimer dementia today, with this number projected to grow to 13.8 million by 2060. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence–Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls

✓ Peer-reviewed alzhub usefulness score 42 out of 100. American Journal of Neuroradiology 2025-07-30

The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of neuropathology and experimental neurology 2004-04-01

Niemann-Pick type C1 disease (NPC1) is an autosomal recessive neurovisceral storage disease caused by the mutation of NPC1 gene, resulting in perturbed intracellular transport of unesterified cholesterol. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Vitamin D receptor gene as a candidate gene for Parkinson disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Annals of human genetics 2011-03-01

Vitamin D and vitamin D receptor (VDR) have been postulated as environmental and genetic factors in neurodegeneration disorders including multiple sclerosis (MS), Alzheimer disease (AD), and recently Parkinson disease (PD). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer disease and associated disorders 2001-10-01

In 6-month trials, measurement error makes a substantial contribution to the variance in ADAS-Cog change scores. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence

✓ Peer-reviewed alzhub usefulness score 41 out of 100. CNS drugs 2008-01-01

Despite the availability of different classes of drugs for the treatment of depressive and anxiety disorders, there are a number of clinically significant unmet needs, such as a high prevalence of treatment resistance, partial response, subsyndromal symptomatology, recurrence and relapse. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Artificial Intelligence–Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration

✓ Peer-reviewed alzhub usefulness score 41 out of 100. American Journal of Roentgenology 2026-09-16

Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neuropathology and experimental neurology 2000-09-01

Exceptional advances have been made in understanding the genetics of how common polymorphisms of the apolipoprotein E gene influence the risk and age of onset of Alzheimer disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Diagnosis of intracranial vasculitis: a multi-disciplinary approach

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neuropathology and experimental neurology 1998-01-01

Intracranial vasculitis, or primary angiitis of the central nervous system (PACNS), is an uncommon, often fatal disorder that frequently responds to aggressive immunosuppressive therapy. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Electrical stimulation of the vagus nerve improves amyloid pathology in delirium superimposed on dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Bioelectronic Medicine 2026-01-16

In AD-like mice surgery induced acute changes in amyloid-β; perioperative treatment with pVNS effectively reduced amyloid-β load, plaque sphericity, and neuronal loss. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessing Cognitive Impairment in the Health and Retirement Study Harmonized Cognitive Assessment Protocol Project: Comparing a Diagnostic Algorithm With a Diagnostic Consensus Panel

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Aging and Health 2025-04-15

BackgroundAccurate classification of cognitive impairment in population studies is challenging. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of Medicare predictors in health disparities in the risk of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-04-01

Low income and vulnerability to arterial hypertension were the primary contributors to AD/ADRD disparities, with cerebrovascular diseases and depression as notable secondary predictors. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping the impact of age and APOE risk factors for late onset Alzheimer's disease on long range brain connections through multiscale bundle analysis

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Brain structure & function 2025-03-20

Alzheimer's disease currently has no cure and is usually detected too late for interventions to be effective. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv (preprint) 2026-09-11

BackgroundTuberous sclerosis complex (TSC) is a rare autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in TSC1 or TSC2, resulting in chronic hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed